Orphan Rare Disease Drug Launch Strategy

Two Labs has extensive experience advising companies about the dynamics of marketing orphan drugs, and can offer knowledge of successful and unsuccessful launches, in this area to help guide the planning and execution of an optimal launch for a new orphan drug therapy.

Orphan Disease – Market Challenges

Orphan Drugs require a different approach in commercial marketing compared to traditional pharmaceutical products. The market for each different orphan disease is miniscule. Two Labs uses launch analogs to provide the pharma industry with a detailed understanding of successfully launched orphan drugs.

Due to the non-traditional approach for these orphan drugs, companies seeking to develop these treatments should be undertaking initiative, ideally in the early stages of Phase II. Some of the recommended initiatives are:

Physician Development
Finding and developing physicians in the area of the particular orphan disease to become champions for the development of the treatment

Patient Development
Identify and encourage these rare patients to enroll in registries, to help build an international community of patients to benefit from the developing therapy

Advocacy Organization Development
Strengthening existing advocacy organization or helping create a new one

Trial Design Optimization
Working with the regulatory agencies to achieve Orphan Drug Designation and ensure proper trial design

Access and Reimbursement Development
Developing appropriate access so that all patients can benefit from the new therapy

Appropriate Pricing
Learn from others to optimize return winning price strategies